Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bayer has partnered with private equity group Apollo to set up a new entity that will handle its long-acting contraceptive ...

The non-profit Drugs for Neglected Diseases initiative (DNDi) has joined forces with pharma group Serum Institute of India ...

The demise of the two programmes still leaves Roche with one Huntington's candidate, the gene therapy RG6662, which is in a ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...

mResvia has been approved in the EU since 2024 to protect adults aged 60 years and older against lower respiratory tract ...

Alector has confirmed that an alliance with GSK to develop two drug candidates for dementia has been terminated in the wake ...

The Evolution Summit is structured around a dynamic agenda of visionary keynote presentations, real-life case studies, and ...

B inhibitor Jascayd (nerandomilast) has been cleared as a twice-daily, oral therapy for adults with IPF as well as ...

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

Though they are still primarily prescribed for weight loss and diabetes, researchers are looking at the effects of GLP-1s for a wide variety of conditions from substance abuse dis ...